OGN

Organon & Co.

September 9, 2026 · intraday

Rarity

1.64

Peak move

−0.80%

Float cap

$3.6B

Organon & Co. is a global healthcare company delivering medicines and solutions in women's health and general medicines, including biosimilars and established brands. Its portfolio spans contraception, fertility, immunology, oncology, and more, with a focus on health needs that disproportionately affect women. Products reach over 140 countries through wholesalers, retailers, hospitals, government agencies, and managed care providers.

• peer_disclosureSep 9

  Sandoz unveiled its Bio100 ambition to expand its biosimilar portfolio from 13 products to over 100 by 2040 and more than double net sales by 2035, investing about $300m in a new biosimilar facility in Slovenia.

  Webpharmamanufacturing.com
• peer_disclosureSep 8 · 06:32 ET

  Moody's and S&P raised Sun Pharmaceutical Industries' credit rating to investment grade (Baa1/BBB+) following its $11.75bn bid to acquire Organon & Co., with the deal expected to close by early 2027.

  Webm.economictimes.com